Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

Completed · Phase 1

Conditions studied: Drug-induced Weight Gain

In brief

This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.

Key facts

Study ID
NCT05857566
Run by
Response Pharmaceuticals
People needed
24
Starts
2023-05-16
Expected to finish
2023-09-13
Last updated by the study team
2023-11-18

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.